Patent · US Active

3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

US10596179B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

CELGENE CORPORATION · US

Inventors

Peter Schafer · Ottersheim, DE
Lei Wu · San Diego, US
Ying Ye · Pleasanton, US

Key dates

Filing date	Mar 1, 2019
Grant date	Mar 24, 2020
Priority date	—
Expiry date	Mar 1, 2039

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.